[HTML][HTML] Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week …
PJ Mease, D van der Heijde, CT Ritchlin… - Annals of the …, 2017 - ard.bmj.com
Objective To assess the safety and efficacy of ixekizumab, a monoclonal antibody that
inhibits interleukin-17A, in a double-blind phase III trial enrolling patients with active …
inhibits interleukin-17A, in a double-blind phase III trial enrolling patients with active …
Ustekinumab for psoriatic arthritis
RS Cuchacovich, LR Espinoza - The Lancet, 2009 - thelancet.com
The systemic and complex nature of psoriasis is shown by the coexistence of various clinical
disorders, including eye and intestinal problems, metabolic syndrome, and joint …
disorders, including eye and intestinal problems, metabolic syndrome, and joint …
[HTML][HTML] Cutaneous lesions from IFN-α-induced sarcoidosis: how do we reverse the effects?
RS Cuchacovich, I Garcia-Valladares… - Expert Review of …, 2011 - Taylor & Francis
Chronic infection with hepatitis C virus (HCV) causes significant morbidity and mortality and
is the principal cause of parenterally transmitted non-A, non-B hepatitis around the world. It …
is the principal cause of parenterally transmitted non-A, non-B hepatitis around the world. It …
Cerebrovascular disease in systemic lupus erythematosus (SLE): Lack of association with anticardiolipin (aCL) antibodies
R Singh, RS Cuchacovich, W Huang… - JCR: Journal of …, 2002 - journals.lww.com
Central nervous system (CNS) involvement is an important clinical manifestation of systemic
lupus erythematosus (SLE), and a leading cause of death in these patients (1, 2). A wide …
lupus erythematosus (SLE), and a leading cause of death in these patients (1, 2). A wide …
[CITATION][C] Does TNF alpha blockade contribute to insulin resistance (IR) in rheumatoid arthritis (RA) patients?
RS Cuchacovich, H Thompson… - ARTHRITIS …, 2007 - WILEY-LISS DIV JOHN WILEY & …